Tivantinib (ARQ197) in hepatocellular carcinoma

References

• Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S169-71
   Google Scholar
• Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007;4:424-32
   PubMedGoogle Scholar
• Harding JJ, Abou-Alfa GK. Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer 2014;120:3122-30
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Pressiani T, Boni C, Rimassa L, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013;24:406-11
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C. Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. World J Hepatol 2010;2:103-13
   Google Scholar
• Shao YY, Wu CH, Lu LC, et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J Hepatol 2014;60:313-18
   PubMed Web of Science ®Google Scholar
• Finn RS. Survival after sorafenib: expect the unexpected. J Hepatol 2014;60:243-4
   PubMedGoogle Scholar
• Eng C, Hart LL, Severtsev A, et al. A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. J Clin Oncol 2013;31(Suppl):3508
   Google Scholar
• Hepatocyte Growth Factor/ Scatter Factor (HGF/SF), MET and cancer references. Available from: www.vai.org/MET/Index.aspx
   Google Scholar
• Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:553-72
   PubMed Web of Science ®Google Scholar
• Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009;19:542-51
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103
   PubMed Web of Science ®Google Scholar
• Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997;94:701-6
   PubMed Web of Science ®Google Scholar
• Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768-71
   PubMed Web of Science ®Google Scholar
• Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60-6
   PubMed Web of Science ®Google Scholar
• Chmielowiec J, Borowiak M, Morkel M, et al. C-Met is essential for wound healing in the skin. J Cell Biol 2007;177:151-62
   PubMed Web of Science ®Google Scholar
• Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004;287:F7-16
   PubMed Web of Science ®Google Scholar
• Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Mammadova G, Song R, et al. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J Cell Sci 2006;119:4623-33
   Google Scholar
• Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-71
   PubMed Web of Science ®Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61
   PubMed Web of Science ®Google Scholar
• Jahangiri A, De Lay M, Miller LM, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013;19:1773-83
   PubMed Web of Science ®Google Scholar
• Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014;7:1001-14
   PubMed Web of Science ®Google Scholar
• Kiss A, Wang NJ, Xie JP, et al. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997;3:1059-66
   PubMed Web of Science ®Google Scholar
• Ljubimova JY, Petrovic LM, Wilson SE, et al. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 1997;45:79-87
   PubMed Web of Science ®Google Scholar
• Okano J, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver 1999;19:151-9
   PubMedGoogle Scholar
• Osada S, Kanematsu M, Imai H, et al. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 2008;55:544-9
   PubMed Web of Science ®Google Scholar
• Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009;49:491-503
   PubMed Web of Science ®Google Scholar
• Wang ZL, Liang P, Dong BW, et al. Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg 2008;12:327-37
   PubMed Web of Science ®Google Scholar
• Horiguchi N, Takayama H, Toyoda M, et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 2002;21:1791-9
   Google Scholar
• Zhang SZ, Pan FY, Xu JF, et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 2005;4:1577-84
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012;9:378-90
   Google Scholar
• Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544-53
   PubMed Web of Science ®Google Scholar
• Basilico C, Pennacchietti S, Vigna E, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013;19:2381-92
   PubMed Web of Science ®Google Scholar
• Katayama R, Aoyama A, Yamori T, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013;73:3087-96
   PubMed Web of Science ®Google Scholar
• Kanteti R, Dhanasingh I, Kawada I, et al. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS ONE 2014;9:e105919
   PubMedGoogle Scholar
• Chen TH, Chan PC, Chen CL, Chen HC. Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition. Oncogene 2011;30:153-66
   Google Scholar
• Remsing Rix LL, Kuenzi BM, Luo Y, et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol 2014;9:353-8
   PubMedGoogle Scholar
• Shuai LU, Antonia R, Frank TK, et al. Poster sessions - anti-proliferative mechanisms downstream of c- met of the kinase inhibitor tivantinib (ARQ 197). Hepatology 2013;58:92A-207A
   Google Scholar
• Murai T, Takakusa H, Nakai D, et al. Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica 2014;44:996-1008
   PubMed Web of Science ®Google Scholar
• Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271-9
   PubMed Web of Science ®Google Scholar
• Santoro A, Simonelli M, Rodriguez-Lope C, et al. A phase-1b study of tivantinib (ARQ197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 2013;108:21-4
   PubMed Web of Science ®Google Scholar
• Puzanov I, Sosman J, Santoro A, et al. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs 2015;33:159-68
   PubMed Web of Science ®Google Scholar
• Rimassa L, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14:55-63
   Google Scholar
• Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31:4105-14
   PubMed Web of Science ®Google Scholar
• Takai K, Hara J, Matsumoto K, et al. Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood 1997;89:1560-5
   PubMed Web of Science ®Google Scholar
• Matsuda-Hashii Y, Takai K, Ohta H, et al. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. Exp Hematol 2004;32:955-61
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-46
   PubMed Web of Science ®Google Scholar
• You H, Ding W, Dang H, et al. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011;54:879-89
   PubMed Web of Science ®Google Scholar
• E7050 in combination with sorafenib versus sorafenib alone as first line therapy in patients with hepatocellular carcinoma. Available from: www.clinicaltrials.gov/ct2/show/NCT01271504?term=e7050&rank=6 [Last accessed 7th November 2014]
   Google Scholar
• Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011;286:2066-76
   Google Scholar